Medical therapy for sudden death

Pediatric Clinics of North America

Volumn 51, Issue 5, 2004, Pages 1379-1387

  Balaji, Seshadri ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIALLERGIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ASTEMIZOLE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COTRIMOXAZOLE; DISOPYRAMIDE; ERYTHROMYCIN; LIDOCAINE; MAGNESIUM; METOPROLOL; MEXILETINE; NADOLOL; NEUROLEPTIC AGENT; NICORANDIL; PHENOTHIAZINE; PHENYTOIN; PINACIDIL; POTASSIUM; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; SODIUM CHANNEL; SOTALOL; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL;

ACTION POTENTIAL; BRUGADA SYNDROME; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; ELECTROLYTE BALANCE; FAMILY HISTORY; GENE MUTATION; GENETICS; GENOTYPE; HEART ARRHYTHMIA; HEART FAILURE; HEART PACING; HEART PROARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; LIFESTYLE; LONG QT SYNDROME; MORTALITY; NONHUMAN; PACEMAKER; PROPHYLAXIS; QT INTERVAL; REPOLARIZATION; REVIEW; STRESS; SUDDEN DEATH; TACHYCARDIA; TORSADE DES POINTES;

CARDIOMYOPATHY, HYPERTROPHIC; CHILD; DEATH, SUDDEN, CARDIAC; HEART DEFECTS, CONGENITAL; HEART FAILURE, CONGESTIVE; HUMANS; LIFE STYLE; LONG QT SYNDROME;

EID: 4344579902     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2004.04.002     Document Type: Review

References (40)

1. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 324(12):1991;781-788
2. Jervell A., Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T Interval, and sudden death. Am Heart J. 54(1):1957;59-68
3. Garson A. Jr., Dick M. II, Fournier A., et al. The long QT syndrome in children. An international study of 287 patients. Circulation. 87(6):1993;1866-1872
4. Krahn A.D., Yee R., Chauhan V., et al. Beta blockers normalize QT hysteresis in long QT syndrome. Am Heart J. 143(3):2002;528-534
5. Eldar M., Griffin J.C., Van Hare G.F., et al. Combined use of beta-adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol. 20(4):1992;830-837
6. Itoh T., Kikuchi K., Odagawa Y., et al. Correlation of genetic etiology with response to beta-adrenergic blockade among symptomatic patients with familial long-QT syndrome. J Hum Genet. 46(1):2001;38-40
7. Ackerman M.J. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc. 73(3):1998;250-269
8. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 92(12):1995;3381-3386
9. Compton S.J., Lux R.L., Ramsey M.R., et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation. 94(5):1996;1018-1022
10. Carlsson L., Abrahamsson C., Drews L., et al. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation. 85(4):1992;1491-1500
11. Sato T., Hata Y., Yamamoto M., et al. Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome. J Cardiovasc Electrophysiol. 6(4):1995;279-282
12. + channel opener in the LQT1 form of congenital long-QT syndrome. Circulation. 97(16):1998;1581-1588
13. Khan I.A. Long QT syndrome: diagnosis and management. Am Heart J. 143(1):2002;7-14
14. Schwartz P.J., Priori S.G., Spazzolini C., et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 103(1):2001;89-95
15. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA. 287(10):2002;1308-1320
16. McKenna W.J., Behr E.R. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart. 87(2):2002;169-176
17. Ostman-Smith I., Wettrell G., Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol. 34(6):1999;1813-1822
18. McKenna W.J., Oakley C.M., Krikler D.M., et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J. 53(4):1985;412-416
19. Oechslin E.N., Harrison D.A., Connelly M.S., et al. Mode of death in adults with congenital heart disease. Am J Cardiol. 86(10):2000;1111-1116
20. Garson A. Jr., Randall D.C., Gillette P.C., et al. Prevention of sudden death after repair of tetralogy of Fallot: treatment of ventricular arrhythmias. J Am Coll Cardiol. 6(1):1985;221-227
21. Saul J.P., Alexander M.E. Preventing sudden death after repair of tetralogy of Fallot: complex therapy for complex patients. J Cardiovasc Electrophysiol. 10(9):1999;1271-1287
22. Roos-Hesselink J., Perlroth M.G., McGhie J., et al. Atrial arrhythmias in adults after repair of tetralogy of Fallot. Correlations with clinical, exercise, and echocardiographic findings. Circulation. 91(8):1995;2214-2219
23. Garson A. Jr., Bink-Boelkens M., Hesslein P.S., et al. Atrial flutter in the young: a collaborative study of 380 cases. J Am Coll Cardiol. 6(4):1985;871-878
24. Balaji S., Johnson T.B., Sade R.M., et al. Management of atrial flutter after the Fontan procedure. J Am Coll Cardiol. 23(5):1994;1209-1215
25. Triedman J.K., Alexander M.E., Love B.A., et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol. 39(11):2002;1827-1835
26. Priori S.G., Napolitano C., Gasparini M., et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 105(11):2002;1342-1347
27. Alings M., Wilde A. "Brugada" syndrome: clinical data and suggested pathophysiological mechanism. Circulation. 99(5):1999;666-673
28. Burns J.C., Shike H., Gordon J.B., et al. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol. 28(1):1996;253-257
29. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 335(26):1996;1933-1940
30. Heidenreich P.A., Keeffe B., McDonald K.M., et al. Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death. Am Heart J. 144(3):2002;422-430
31. Pitt B., Zannad F., Remme W.J., et al. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 341(10):1999;709-717
32. Aronson D., Burger A.J. Concomitant beta-blocker therapy is associated with a lower occurrence of ventricular arrhythmias in patients with decompensated heart failure. J Card Fail. 8(2):2002;79-85
33. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 106(17):2002;2194-2199
34. Rankovic V., Karha J., Passman R., et al. Predictors of appropriate implantable cardioverter-defibrillator therapy in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 89(9):2002;1072-1076
35. Ellison K.E., Hafley G.E., Hickey K., et al. Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). Circulation. 106(21):2002;2694-2699
36. Sumitomo N., Harada K., Nagashima M., et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 89(1):2003;66-70
37. Priori S.G., Napolitano C., Memmi M., et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 106(1):2002;69-74
38. Faber T.S., Zehender M., Just H. Drug-induced torsade de pointes. Incidence, management and prevention. Drug Saf. 11(6):1994;463-476
39. Anastasiou-Nana M.I., Anderson J.L., Stewart J.R., et al. Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable proarrhythmic effect. Am Heart J. 113(5):1987;1071-1077
40. Wolbrette D.L. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 91(6A):2003;39D-44D